ESMO: Pembrolizumab + Chemo, Trastuzumab Beneficial in Gastroesophageal Cancer

WEDNESDAY, Oct. 25, 2023 -- For patients with HER2-positive gastroesophageal junction (GEJ) adenocarcinoma, pembrolizumab improves progression-free survival when combined with chemotherapy and trastuzumab, according to a study published online Oct....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news